AVITA Medical, Inc. reported $76M of revenue over the trailing twelve months, +1.00% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $76M (to Q2 2026). Net income: −$43M, trailing twelve months to Q2 2026. Free cash flow: −$26M, trailing twelve months to Q2 2026. Operating margin: −48%, trailing twelve months to Q2 2026.

RCELAVITA Medical, Inc.

Healthcare

$3.92-21% 1Y

$3.92

$3.2752 weeks$13.35

Latest close: a new 52-week highOct 8, 2026what changed →

RCEL as reported

AVITA Medical, Inc. reported $76M of revenue over the trailing twelve months, +1.00% on the year before. 11 reported series are charted on this page, each one as filed.

$76M

Revenue, trailing twelve months · to Q2 2026 · +1.00% against the twelve months before

Net income: −$43M
Net income · −16% year on year · trailing twelve months to Q2 2026
Free cash flow: −$26M
Free cash flow · −38% year on year · trailing twelve months to Q2 2026
Operating margin: −48%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for RCEL, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$76M	+1.00%	Q2 2026
Net income	−$43M	−16%	Q2 2026
EPS	−$1.43	−27%	Q2 2026
Gross margin	82%	n/a	Q2 2026
Operating margin	−48%	n/a	Q2 2026
Net margin	−58%	n/a	Q2 2026
ROE	343%	n/a	Q2 2026
ROA	−85%	n/a	Q2 2026
ROIC	−213%	n/a	Q2 2026
Free cash flow	−$26M	−38%	Q2 2026
P/E	14.5	n/a	Q1 2023 · 13 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.